Healthy Spinoffs, Happy Investors

When Cardinal Health spun off its medical technology and equipment businesses in September as CareFusion, Cardinal, a maker and distributor of medical and surgical supplies, said this action would lead to "enhanced management focus and sharper strategic vision."

It will take time to determine if this spinoff produces enduring higher share prices. However, in the world of high-profile medical deals, the strategy can work very nicely ... at least for the spinoff's shareholders.

Take a look at the table below, which examines some big spinoffs -- as recent as February's Bristol-Myers Squibb (NYSE: BMY  ) spinoff of Mead Johnson Nutrition or as early in the decade as Merck's (NYSE: MRK  ) spinoff of Medco Health Solutions. In each case, the spinoff has outperformed the parent.

Spinoff Date

Parent Company

Return Since Spinoff

Spun-Off Company

Return Since Spinoff

Aug. 9, 2001

Bristol-Myers Squibb

(42.1%)

Zimmer Holdings

84.7%

June 23, 2000

Baxter International

105.5%

Edwards LifeSciences

259.1%

Feb. 11, 2009

Bristol-Myers Squibb

3.7%

Mead Johnson Nutrition

70.1%

Aug. 21, 2003

Merck

(17.7%)

Medco Health Solutions

334.8%

May 3, 2004

Abbott Labs (NYSE: ABT  )

37.7%

Hospira

66.0%

Sources: Yahoo! Finance and Capital IQ, a division of Standard & Poor's.
Return calculated from closing price of first day post-spinoff through Oct. 9, 2009.

That collection reflects a variety of products and strategies. Mead Johnson had been part of its corporate parent since the old Bristol-Myers bought it in 1967, even before the merger that led to Bristol-Myers Squibb. However, Bristol-Myers hasn't severed ties with Mead Johnson -- it still owns 83.1% of the outstanding stock and has 97.5% of voting power.

On the other hand, Merck bought the Medco Containment Services pharmacy-benefits management company in 1993, but the combination didn't last long. All of the renamed Medco Health Solutions was spun off in August 2003.

What's next?
Spinoffs don't guarantee success. Still, these results should offer an education for shareholders of Pfizer (NYSE: PFE  ) , who wonder if their company can effectively absorb all of Wyeth (NYSE: WYE  ) . The same goes for any Merck shareholders who question if acquiring Schering-Plough (NYSE: SGP  ) might cause indigestion down the road.

The buyers say they'll keep all of their acquisitions, aside from divestitures required by antitrust regulators. But what happens when the corporate game plan changes? Another spinoff, as executives talk about the strategic sagacity of separating certain business units?

Just remember: Today's spinoff could be tomorrow's takeover target. Exhibit A is Eli Lilly's (NYSE: LLY  ) 1995 spinoff of medical-device maker Guidant, which was acquired by Boston Scientific in April 2006. I don't know if all investors were satisfied with that one. Guidant shareholders got $42 in cash and $38 in Boston Scientific stock, but that stock is down 54% since the deal closed.

However, I'm sure the investment bankers who engineered both the original spinoff and the subsequent acquisition were happy.

What spinoffs have you participated in, and have they worked out well for you or not? Let us know in the comments section below.

Fool contributor Robert Steyer doesn't own shares of any companies cited in this story. Medco Health Solutions is a Motley Fool Stock Advisor recommendation. Pfizer is an Inside Value selection. The Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 12, 2009, at 3:33 PM, au90cu10 wrote:

    Nice article ... perhaps a more detailed article on

    the subject of spinoffs (keep or sell) , would be of

    benefit to readers .

    I have held VZ for a few years now and they have

    spun off 2 units, both of which I elected to keep and

    both tanked to under a dollar , now, I am faced with

    the next VZ spinoff to FTR and not sure whether to

    hold the FTR or sell and buy more VZ. This one appears

    to be different from the previous 2 ( Idearc and FTP) ,

    in that not nearly as much debt will be sent off and

    there is that temp company(SPIN) that the shares will

    be spun off to, then absorbed by FTR ..

    thank you much ...... garce

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1005130, ~/Articles/ArticleHandler.aspx, 10/23/2014 3:37:30 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement